Aptose Biosciences Stock Today
| APS Stock | CAD 0.25 0.01 3.85% |
Performance0 of 100
| Odds Of DistressOver 88
|
Aptose Biosciences is selling at 0.25 as of the 30th of November 2024; that is 3.85 percent decrease since the beginning of the trading day. The stock's open price was 0.26. Aptose Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Aptose Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada. The company has 59.52 M outstanding shares of which 2.36 K shares are presently shorted by private and institutional investors with about 0.48 days to cover all short positions. More on Aptose Biosciences
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Aptose Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Aptose Biosciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Aptose Biosciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman, CEO and Pres | William Rice | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Aptose Biosciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Aptose Biosciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsAptose Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aptose Biosciences' financial leverage. It provides some insight into what part of Aptose Biosciences' total assets is financed by creditors.
| |||||
Aptose Biosciences (APS) is traded on Toronto Exchange in Canada and employs 35 people. Aptose Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aptose Biosciences's market, we take the total number of its shares issued and multiply it by Aptose Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Aptose Biosciences operates under Biotechnology sector and is part of Health Care industry. The entity has 59.52 M outstanding shares of which 2.36 K shares are presently shorted by private and institutional investors with about 0.48 days to cover all short positions.
Aptose Biosciences has accumulated about 36.37 M in cash with (44.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aptose Biosciences Probability Of Bankruptcy
Ownership AllocationAptose Biosciences holds a total of 59.52 Million outstanding shares. Aptose Biosciences shows 16.38 percent of its outstanding shares held by insiders and 16.68 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aptose Ownership Details
Aptose Biosciences Risk Profiles
Although Aptose Biosciences' alpha and beta are two of the key measurements used to evaluate Aptose Biosciences' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.36 | |||
| Standard Deviation | 5.26 | |||
| Variance | 27.64 | |||
| Risk Adjusted Performance | (0.13) |
Aptose Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Aptose Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Aptose Biosciences Corporate Management
Elected by the shareholders, the Aptose Biosciences' board of directors comprises two types of representatives: Aptose Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptose. The board's role is to monitor Aptose Biosciences' management team and ensure that shareholders' interests are well served. Aptose Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptose Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brooks MBA | VP Controller | Profile | |
| Philippe Ledru | Senior Officer | Profile | |
| Janet CA | VP Fin | Profile | |
| Rafael MD | Senior Officer | Profile | |
| Roger BSc | Vice Operations | Profile | |
| Marc Wiles | Senior Affairs | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..